134: Clinical Characteristics of Early Onset Non-Infectious Pulmonary Complications following Cord Blood Transplantation  by Wake, A. et al.
Poster Session I 51deplete plasma, but not the RBC. A retrospective analysis was per-
formed on 240 pediatric patients transplanted with PD (128) or
RCR (112) CB. PD CB came from StemCyte and were transplanted
at many US & international centers - 60 ALL, 35 AML, 6 MDS, 5
lymphoma, 4 JMML, and 18 other malignancies. The other patients
received RCR CB products from various CB banks and were trans-
planted at the University of Arizona Medical Center - 56 ALL, 32
AML, 9 CML, 6 MDS, 4 lymphoma, and 5 other malignancies.
Of the 74% PD and 46% RCR cases with known disease status,
27% versus 24% were early, 45% versus 52% intermediate, and
27% and 18% advanced per IBMTR for PD and RCR respectively.
Median age for PD and RCR patients were 6 (range 0.5–15) and 7
years (range 0.5–15) respectively; median weight were 21 kg (range
5–92) for PD and 25 kg (range 7–104) for RCR, with 65%. and 55%
males respectively. Median # HLA ABDR matches were 5.0 for
both groups; however, median pre-freeze and post-thaw TNC
dose were 6.8  107/kg and 5.3  107/kg for PD patients (78% re-
covery) and 4.6  107/kg and 3.3  107/kg for RCR patients (72%
recovery); non-myeloablative conditioning accounted for 12% of
PD and 3% of RCR patients. Cumulative incidence estimates
were used for engraftment (unevaluable category not used), and Ka-
plan-Meier estimates were used for relapse, TRM, OS and RFS
rates. A matched-pair analysis was also performed by matching
a PD patient to each RCD patient based on age, weight, # HLA
matches, cell dose, disease, and disease status if available and are
summarized below. The results demonstrate that 1) Foregoing
RCR may result in higher cell dose products being selected for
transplantation; 2) unrelated PD CBT can be performed safely
with superior engraftment and TRM in diverse pediatric patients
with malignancies, and appear to trend towards improvement for
overall survival on univariate analysis; 3) matched pair analysis
even with cell dose matched may show a potential advantage of
PD CB for platelet engraftment and TRM.
Outcome Summary
Plt Plt 1-Yr 100-Day &ANC500 20 K 50 K Relapse* 1-Yr TRM 1-Yr OS 1-Yr RFS*PD Patients 89 ± 6% 69 ± 6% 65 ± 6% 29 ± 5% 15 ± 3%,
23 ± 4%60 ± 5% 51 ± 5%RCR Patients 85 ± 6% 55 ± 6% 51 ± 6% 17 ± 5%* 30 ± 4%,
45 ± 5%49 ± 5% 44 ± 5%*Cox RR &
P-value
(RCR
Reference)0.81 0.13 1.60 0.007 1.41 0.06 0.49 0.002 0.74 0.11
(for death)Matched Pair
AnalysisANC500 Plt 20 K Plt 50 K Relapse TRM OS RFSP-value NS 0.005 0.02 0.004 NS NSIn favor of PD PD PDNS 5 Not significant.
*Insufficient data on disease status of RCR patients precludes mean-
ingful analysis.134
CLINICAL CHARACTERISTICS OF EARLY ONSET NON-INFECTIOUS PUL-
MONARY COMPLICATIONS FOLLOWING CORD BLOOD TRANSPLANTA-
TION
Wake, A., Uchida, N., Ishiwata, K., Takagi, S., Tsuji, M., Kato, D.,
Yamamoto, H., Seo, S., Matsuno, N., Masuoka, K., Miyakoshi, S.,
Makino, S., Yoneyama, A., Taniguchi, S. Toranomon Hospital, Tokyo,
Japan.
Early onset non-infectious pulmonary complications (EONIPC),
such as idiopathic pneumonia syndrome (IPS) are fatal disorders
following allogeneic SCT. There has been little information on
NIPC following cord blood transplantation (CBT). We tried to
characterize NIPC after CBT.
We reviewed medical records of 246 patients (291 transplants)
with hematological diseases who had received CBT between Jan.2002 and Dec. 2006 at Toranomon Hospital, Tokyo, Japan. Median
age was 55 years (17–79). Most of them had diseases in advanced sta-
tus (n5 255). Most of the pre-transplant conditioning were reduced
intensity consisted of fludarabine, melphalan and TBI 4Gy (n 5
223). Most of GVHD prophylaxis were calcineurin inhibitor only;
cyclosporine (CSP) (n 5 102) or tacrolimus (Tac) alone (n 5
173). HLA disparities were as follows; 6/6 (n 5 14), 5/6 (n 5 73),
4/6 (n 5 198), and 3/6 (n 5 6). Diagnosis of NIPC was made by
Chest X-ray, computed tomography, bronchoscopy, and pulmo-
nary function test. Infectious complications were excluded by posi-
tive result of culture, galactomannan test, and RT-PCR of sputum,
pleural effusion and BAL fluid.
The incidence of NIPC was 33.7% (n 5 98). EONIPC (95 pa-
tients) were developed within 100 days after transplant (median,
17 days, range, 2–57), which can be subdivided into 2 on the basis
of presence (n 5 48) or absence (n 5 47) of pleural effusion (PE).
Late onset NIPC (LONIPC) were observed in only 11 cases
(4.5%), including 3 cases of COP, 6 of IP, and 2 of BO. Multivariate
analysis revealed 3 risk factors for EONIPC with PE; GVHD pro-
phylaxis with CSP over Tac (p 5 0.036, RR 1.65), grade III-IV
acute GVHD over grade 0-II (p 5 0.007, RR 1.84), and 2 and
greater HLA mismatch over less than 2 (p 5 0.046, RR 1.587).
The CT finding of NIPC with PE revealed ground-glass opacity
of lung field, similar to that of COP. NIPC with PE responded fa-
vorably to low dose corticosteroid therapy as same as COP. In con-
trast to low 1-year overall survival (OS) of NIPC without PE
(11.1%, 95%CI: 1.9–20.3), that of NIPC without PE was signifi-
cantly high (53.1%, CI: 38.8–67.4).
The incidence of EONIPCs was high, whereas that of LONIPCs
was low after reduced-intensity CBT using single calcineurin inhib-
itor as GVHD prophylaxis. Further accumulation and more precise
investigation of laboratory and clinical data are warranted to clarify
the biological mechanism of EONIPC with PE and without PE or
to descriminate IPS from engraftment syndrome or capillary leak
syndrome.135
A TWO STEP APPROACH TO HAPLOIDENTICAL ALLOGENEIC HEMATO-
POIETIC STEM CELL TRANSPLANTATION (HSCT) FOR HIGH RISK PA-
TIENTS WITH HEMATOLOGIC DISORDERS
Grosso, D., Brunner, J., Carabasi, M., Dessain, S., Filicko-O’Hara, J.,
Mookerjee, B., O’Hara, W., Tedesco, N., Wagner, J.L.,
Flomenberg, N. Thomas Jefferson University, Philadelphia, PA.
Post transplant cyclophosphamide (CTX) has been utilized to in-
duce donor host tolerance in allogeneic HSCT. While promising,
the long term risk of MDS and AML from exposure of the graft
to CTX is unknown, and the optimal T cell dose to deliver using
this approach remains undefined. To address these issues, 12
high-risk patients underwent haploidentical HSCT from related
donors for disorders of hematopoiesis using a two step approach.
Nine of 12 (75%) patients had evidence of disease at the time of
HSCT. In the GVH direction, 10 of 12 were 4/8 matches with their
donors at HLA-A, B, C and DRB1; the other 2 patients were 5/8
and 6/8 matches. Nine of the 12 patients were given a myeloablative
conditioning regimen of TBI (1.5 Gy) BID on days -9 through -6.
Three received a nonmyeloablative conditioning regimen of fludar-
abine and ARA-C on days-11 through -8 and one 2 Gy fraction of
TBI on day -6. The patients received 2  108/kg of their donor’s
CD31 lymphocytes after completion of TBI on day -6, followed
by rest days on day -5 and -4. On days -3 and -2, CTX was given
at a dose of 60 mg/kg/day for the purpose of tolerization of the do-
nor lymphocytes. On day 0, donor CD341 cells were infused. When
possible, the number of non-tolerized T-cells in the CD341 prod-
uct was limited to 5  104/kg. Tacrolimus and CellCept were used
as GVHD prophylaxis. All of the patients developed fevers between
DLI and CTX. Some patients also developed mild diarrhea and
a rash, which in one case was biopsy-positive for GVHD. All pa-
tients engrafted. GVHD was generally mild, and easily controlled
with corticosteroids which could be rapidly tapered in all but one
patient. Five patients have died, three of relapsed disease and two
of infections. An additional patient is alive, but with relapsed dis-
ease. Six patients are well and in CR at a range of 19–298 days
